LV12291A - Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity - Google Patents

Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity

Info

Publication number
LV12291A
LV12291A LV990027A LV990027A LV12291A LV 12291 A LV12291 A LV 12291A LV 990027 A LV990027 A LV 990027A LV 990027 A LV990027 A LV 990027A LV 12291 A LV12291 A LV 12291A
Authority
LV
Latvia
Prior art keywords
triptase
activity
compound
treatment
pharmaceutical compositions
Prior art date
Application number
LV990027A
Other languages
Latvian (lv)
Other versions
LV12291B (en
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rucywen Wang
Wendy Beth Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of LV12291A publication Critical patent/LV12291A/en
Priority to LVP-00-30A priority Critical patent/LV12458B/en
Priority to LVP-00-31A priority patent/LV12459B/en
Publication of LV12291B publication Critical patent/LV12291B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to novel compounds which are typtase inhibitors; the pharmaceutically acceptable salts and N oxides thereof; their uses as therapeutic agents and the methods of their making.
LVP-99-27A 1996-07-30 1999-02-18 Novel compounds and compositions for treating diseases associated with tryptase activity LV12291B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-00-30A LV12458B (en) 1996-07-30 2000-02-25 Novel compounds and compositions for treating diseases associated with tryptase activity
LVP-00-31A LV12459B (en) 1996-07-30 2000-02-25 Novel compounds and compositions for treating diseases associated with tryptase activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
LV12291A true LV12291A (en) 1999-06-20
LV12291B LV12291B (en) 2000-04-20

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-27A LV12291B (en) 1996-07-30 1999-02-18 Novel compounds and compositions for treating diseases associated with tryptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (en)
JP (1) JP2001509787A (en)
KR (1) KR20000029679A (en)
CN (1) CN1073103C (en)
AU (1) AU733621B2 (en)
CA (1) CA2262542A1 (en)
CZ (1) CZ29799A3 (en)
EE (1) EE9900036A (en)
FI (1) FI990171A (en)
HU (1) HUP0003267A3 (en)
LV (1) LV12291B (en)
NO (1) NO990433L (en)
NZ (1) NZ333713A (en)
PL (1) PL331465A1 (en)
SI (1) SI9720047A (en)
SK (1) SK8599A3 (en)
WO (1) WO1998004537A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
EP1060171A2 (en) * 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase inhibitors
ES2233025T3 (en) * 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. AGENT INHIBITORS OF TRIPTASE.
AU5625499A (en) * 1998-09-04 2000-03-27 Altana Pharma Ag Novel pyranoses
DE60014932T2 (en) 1999-08-10 2005-10-13 Altana Pharma Ag DIAZOCINDION DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS
AU778965B2 (en) * 1999-09-14 2004-12-23 Altana Pharma Ag Tryptase inhibitors
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
DE19955476A1 (en) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments
CA2392127A1 (en) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
TR200402322T4 (en) * 1999-12-20 2004-12-21 Altana Pharma Ag Tryptase inhibitors
DK1358182T3 (en) * 2001-01-31 2004-12-20 Altana Pharma Ag Diazocin derivatives and their use as tryptase inhibitors
ATE349427T1 (en) 2001-02-21 2007-01-15 Altana Pharma Ag TRYPTASE INHIBITORS
CA2438711A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
US20040087792A1 (en) * 2001-03-15 2004-05-06 Thomas Martin Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
AU2002345664C1 (en) 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2278928T3 (en) 2001-06-19 2007-08-16 Altana Pharma Ag TRIPTASE INHIBITORS.
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
TWI432188B (en) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
AU2009328497A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
FR3038605B1 (en) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE
CN110869362A (en) * 2017-05-12 2020-03-06 国立研究开发法人理化学研究所 Modified class A GPCR binding compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
JPH08507768A (en) * 1993-03-12 1996-08-20 アリス ファーマシューティカル コーポレイション Compositions and methods for the treatment of immune-mediated inflammatory diseases
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH10501238A (en) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション Compositions and methods for treating mast cell mediated conditions
SI9520101A (en) * 1994-09-23 1997-12-31 Arris Pharm Corp Compositions and methods for treating mast-cell inflammatory condition
KR19980703261A (en) * 1995-03-24 1998-10-15 다니엘 이이치. 페트리 Reversible protease inhibitor
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
AU733621B2 (en) 2001-05-17
JP2001509787A (en) 2001-07-24
FI990171A (en) 1999-03-23
SI9720047A (en) 1999-08-31
FI990171A0 (en) 1999-01-29
HUP0003267A3 (en) 2002-02-28
NO990433D0 (en) 1999-01-29
CN1226892A (en) 1999-08-25
AU3967097A (en) 1998-02-20
CN1073103C (en) 2001-10-17
SK8599A3 (en) 2000-03-13
CA2262542A1 (en) 1998-02-05
NZ333713A (en) 2000-12-22
PL331465A1 (en) 1999-07-19
KR20000029679A (en) 2000-05-25
EP0934293A1 (en) 1999-08-11
EE9900036A (en) 1999-08-16
NO990433L (en) 1999-03-25
CZ29799A3 (en) 1999-06-16
HUP0003267A2 (en) 2001-06-28
LV12291B (en) 2000-04-20
WO1998004537A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
LV12291A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
ATE189218T1 (en) BICYCLIC DIARYLHETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS
DE60114994D1 (en) PLATELET ADP RECEPTOR INHIBITORS
EA200300776A1 (en) FENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
EA200100971A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS
BG66085B1 (en) Phenylalanine derivatives
FI20115753A (en) Pharmaceutical compositions for the treatment of diseases caused by IL-6 production
BR0115411A (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
ES2191069T3 (en) DIARIL-2- (5H) -FURANONAS AS COX-2 INHIBITORS.
EA200500018A1 (en) BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION
ATE227293T1 (en) 2,3-DISUBSTITUTED-(5,6)-HETEROARYL CONDENSED - PYRIMIDINE-4-ONE
DE69834500D1 (en) XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAINISHEMIA
ATE269865T1 (en) PYRAZOLO(3,4-G)QUINOXALINE AS PDGF RECEPTOR PROTEIN TYROSINE KINASE INHIBITORS
EA200301203A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS KATEPSIN INHIBITORS
DE69819539D1 (en) ANTITHROMBOTIC AGENTS
EA200400219A1 (en) QUINOLINE DERIVATIVES AND THEIR USE AS ANTI-TUMOR FACILITIES
EA200100140A1 (en) THERAPEUTIC COMPOSITION ON THE BASIS OF FLAVONOIDS FOR APPLICATION IN TREATMENT OF TUMORS BY CYTOTOXIC AGENTS
DK0758312T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
ID21369A (en) PHARMACEUTICAL COMPOSITION FOR HEALING OF DISEASES CAUSED BY VIRUS
ATE286395T1 (en) ANTITHRBOTIC AGENTS
SE9900190D0 (en) New compounds
PT1337246E (en) UTILIZATION OF 6-DIMETHYLAMINOMETHYL-1-PHENYLCYLOHEXANE COMPOUNDS FOR URINARY INCONTINENCE THERAPY
BR0308293A (en) Statin-based therapy to increase cognitive maintenance
LV12459A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
DE69829861D1 (en) 2-AMINOPYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2